Unknown

Dataset Information

0

Chemical Constituents with GNMT-Promoter-Enhancing and NRF2-Reduction Activities from Taiwan Agarwood Excoecaria formosana.


ABSTRACT: Hepatocellular carcinoma (HCC) is considered to be a silent killer, and was the fourth leading global cause of cancer deaths in 2018. For now, sorafenib is the only approved drug for advanced HCC treatment. The introduction of additional chemopreventive agents and/or adjuvant therapies may be helpful for the treatment of HCC. After screening 3000 methanolic extracts from the Formosan plant extract bank, Excoecaria formosana showed glycine N-methyltransferase (GNMT)-promoter-enhancing and nuclear factor erythroid 2-related factor 2 (NRF2)-suppressing activities. Further, the investigation of the whole plant of E. formosana led to the isolation of a new steroid, 7?-hydroperoxysitosterol-3-O-?-d-(6-O-palmitoyl)glucopyranoside (1); two new coumarinolignans, excoecoumarin A (2) and excoecoumarin B (3); a new diterpene, excoeterpenol A (4); and 40 known compounds (5-44). Among them, Compounds 38 and 40-44 at a 100 ?M concentration showed a 2.97 ± 0.27-, 3.17 ± 1.03-, 2.73 ± 0.23-, 2.63 ± 0.14-, 6.57 ± 0.13-, and 2.62 ± 0.05-fold increase in GNMT promoter activity, respectively. In addition, Compounds 40 and 43 could reduce NRF2 activity, a transcription factor associated with drug resistance, in Huh7 cells with relative activity of 33.1 ± 0.2% and 45.2 ± 2.5%. These results provided the basis for the utilization of Taiwan agarwood for the development of anti-HCC agents.

SUBMITTER: Wu HC 

PROVIDER: S-EPMC7181199 | biostudies-literature | 2020 Apr

REPOSITORIES: biostudies-literature

altmetric image

Publications

Chemical Constituents with GNMT-Promoter-Enhancing and NRF2-Reduction Activities from Taiwan Agarwood <i>Excoecaria formosana</i>.

Wu Ho-Cheng HC   Cheng Ming-Jen MJ   Yen Chia-Hung CH   Chen Yi-Ming Arthur YA   Chen Yi-Siao YS   Chen Ih-Sheng IS   Chang Hsun-Shuo HS  

Molecules (Basel, Switzerland) 20200410 7


Hepatocellular carcinoma (HCC) is considered to be a silent killer, and was the fourth leading global cause of cancer deaths in 2018. For now, sorafenib is the only approved drug for advanced HCC treatment. The introduction of additional chemopreventive agents and/or adjuvant therapies may be helpful for the treatment of HCC. After screening 3000 methanolic extracts from the Formosan plant extract bank, <i>Excoecaria formosana</i> showed glycine <i>N</i>-methyltransferase (GNMT)-promoter-enhanci  ...[more]

Similar Datasets

| S-EPMC4749522 | biostudies-literature
| S-EPMC5430593 | biostudies-literature
| S-EPMC8779593 | biostudies-literature
| S-EPMC6117670 | biostudies-literature
2013-04-05 | E-GEOD-38862 | biostudies-arrayexpress
2013-04-05 | E-MTAB-1177 | biostudies-arrayexpress
| S-EPMC5799944 | biostudies-literature
| S-EPMC6273697 | biostudies-other
| PRJNA339651 | ENA
| PRJNA762958 | ENA